An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Torrent Pharma, an Indian drugmaker, has started working with a new supplier to get more semaglutide and hopes to have its medicine back on shelves by the end of August. The brief report says the move aims to restore supply after shortages, but it doesn’t give many details about the size of the new shipment or exactly how the timeline was set. Semaglutide is the active ingredient in popular drugs like Ozempic and Wegovy. In plain terms, it’s a lab-made version of a natural hormone that helps control appetite and blood sugar. It tells the brain you’re less hungry and slows how quickly your stomach empties. Doctors use it for type 2 diabetes and for weight management in people who meet certain medical criteria. The news here is about supply and distribution, not a new study or new health claims. Torrent appears to have had trouble keeping up with demand and has found another company to supply semaglutide so it can fill prescriptions again. The report doesn’t say whether the new supplier is local or overseas, how many doses are expected, or whether there will be any differences in price or formulation. So the concrete takeaway is limited: a drugmaker expects to resume supply by late August, but details remain sparse. Why this matters is straightforward. Lots of people are taking semaglutide-based drugs for diabetes and for weight loss under medical supervision. Shortages can disrupt treatment plans, cause stress for patients and doctors, and lead to waiting lists or higher prices. If Torrent is a major supplier in certain markets, restoring its supply could make it easier for patients who rely on its version of the medicine to get consistent doses again. There are a few caveats. This is a supply-chain update, not a safety or efficacy announcement. The company’s target date is a projection — manufacturing and regulatory hurdles can cause further delays. If you take semaglutide, don’t stop or change your dose without talking to your doctor; they can advise on temporary alternatives. Also note that availability can vary by country and pharmacy, and this report doesn’t address cost or insurance coverage. Bottom line: Torrent says it has a new supplier and hopes to have semaglutide back in supply by the end of August, but details are limited and timelines could change.
Source: ET Pharma